| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | NaN | 57,216 | NaN | NaN |
| Cost of goods sold excluding amortization | NaN | 3,833 | NaN | NaN |
| Research and development | NaN | 29,006 | NaN | NaN |
| Selling, general and administrative | NaN | 62,978 | NaN | NaN |
| Intangible asset amortization | NaN | 1,752 | NaN | NaN |
| Other income | NaN | 2,351 | NaN | NaN |
| Provision (benefit) for income taxes | NaN | 103,185 | NaN | NaN |
| Net loss | -48,567 | -141,187 | -22,586 | -56,701 |
| Depreciation of property and equipment | 273 | 304 | 301 | 498 |
| Stock-based compensation | 2,563 | 2,285 | 2,112 | 5,077 |
| Amortization of premiums and accretion of discounts on marketable securities | 136 | 256 | 495 | 1,302 |
| Loss on sales of marketable securities | NaN | 0 | NaN | NaN |
| Intangible asset amortization | 1,987 | 1,752 | 1,752 | 3,503 |
| Right-of-use asset amortization | 1,267 | 3,807 | NaN | NaN |
| Deferred income taxes | 0 | 103,186 | -5,974 | -15,769 |
| Other non-cash adjustments, net | -280 | 2,334 | -1,390 | -2,887 |
| Accounts receivable | 2,333 | 4,075 | 5,569 | -2,181 |
| Prepaid expenses and other assets | 5,768 | 5,944 | -703 | 6,826 |
| Inventory | -294 | 1,280 | -32 | 2,218 |
| Accounts payable and other liabilities | 1,480 | 9,077 | -10,223 | 16,966 |
| Product revenue allowances | -1,558 | 5,248 | 6,931 | 3,305 |
| Net cash used in operating activities | -50,218 | -29,417 | -31,626 | -48,399 |
| Asset acquisition | NaN | 0 | 0 | 0 |
| Acquisition of intangible asset | 10,000 | NaN | NaN | NaN |
| Purchases of property and equipment | 221 | 102 | 161 | 735 |
| Purchases of marketable securities | 0 | 2,032 | 14,047 | 96,300 |
| Sales and maturities of marketable securities | 30,455 | 47,000 | 35,570 | 125,667 |
| Net cash provided by investing activities | 20,234 | 44,866 | 21,362 | 28,632 |
| Principal payments on finance leases | 776 | 640 | 517 | 834 |
| Tax obligations paid in connection with settlement of restricted stock units | 0 | 0 | 0 | 915 |
| Net cash used in financing activities | -776 | -640 | -517 | -1,749 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -57 | 20 | -180 | 183 |
| Net change in cash, cash equivalents and restricted cash | -30,817 | 14,829 | -10,961 | -21,333 |
| Beginning of period | 85,320 | 32,294 | 102,785 | NaN |
| End of period | 54,503 | 14,829 | 70,491 | NaN |
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)